UAB Imunodiagnostika implements the project “Innovative tools for allergy diagnostics and treatment” (project No. J05-LVPA-K-03-0086) according to the 2014-2020. Measure No. of the European Union Funds Investment Operational Program Priority 1 “Promotion of Research, Experimental Development and Innovation” J05-LVPA-K “Intelligence. Joint Science-Business Projects ”, which is funded by the European Regional Development Fund. The aim of the project is to develop a globally innovative product of biotechnological commercial value - recombinant proteins with diagnostic properties of reagents. During the project, the company will add new equipment to its existing infrastructure, which will be used for research and development of a new product. The recombinant proteins / allergens developed during the project will meet the rapidly changing market realities:
• The developed technology will allow economical and standardized production of large quantities of recombinant allergens, which will be superior to those produced by other methods.
• The development of highly immunoreactive recombinant allergens would significantly improve the sensitivity and specificity of diagnostic tests;
• Recombinant allergens / proteins produced in the plant system would replace native allergen proteins in immunotherapy